A simple proposal to make STAP protocols clearer 日本語版はこちら By Jun Seita Detection of a GFP signal driven by the Oct3/4 promoter was extensively used to define STAP cells in the original STAP papers [1, 2] and similar approaches have been employed by many third-party attempts to reproduce STAP cells. On the other hand, it […]
Guest post by Dr. Jun Seita: A simple proposal to make STAP protocols clearer Read More »
The California Stem Cell Agency, CIRM, has a new board member. Actress, writer, and Alzheimer’s Disease (AD) advocate Lauren Miller recently joined the ICOC Board of CIRM via an appointment by Governor Jerry Brown. Miller and her husband, Seth Rogen, have both been active as AD advocates and formed an amazing organization to boost AD
Interview with Actress, Writer, Advocate and New CIRM Board Member Lauren Miller Read More »
An FDA committee began a meeting yesterday that continues today to consider permitting new assisted reproduction-based “3-parent” technology that could address mitochondrial disorders, a serious human health problem. The technology also raises complex health issues of its own and invokes ethical questions. The goal of the FDA meeting is articulated this way: “the committee will
Why the FDA should not green-light 3-parent reproduction Read More »
What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time
Interview with Robert Klein on CIRM’s Future Read More »
One of the big stem cell-related stories of 2013 was the controversy over the Stamina Foundation in Italy and its potential use of largely untested stem cell products on patients, including mostly children. The winner of my 2013 Stem Cell Person of the Year Award was Dr. Elena Cattaneo and one reason she won was the courage
Nature Slams Controversial Stamina Foundation: A Dangerous Situation Continues Read More »
The Knoepfler Lab conducts stem and cancer cell as well as chromatin/epigenetics research at the UC Davis School of Medicine. Our team has two big picture goals: (1) catalyzing the development of more effective treatments for cancers based on targeting stem cell-related machinery in tumorigenesis and (2) producing safer stem cell-based regenerative medicine therapies. We are particularly
A big, fat elephant in “the room” of the commercial stem cell field today is something called stromal vascular fraction or SVF, made from human fat tissue or adipose. If you care at all about stem cells or the stem cell field more generally, you had better educate yourself on SVF. You can learn a
Law and Order SVF: what is stromal vascular fraction? Read More »
A team at the Weizmann Institute of Science in Israel led by Jacob Hanna reports today near perfect reprogramming efficiency to make induced pluripotent stem cells (iPSCs) by eliminating a single factor called Mbd3 from the cellular equation. On first glance, the Nature article (Rais, et al.) seems to be all about boosting cellular reprogramming efficiency to close
100% reprogramming efficiency reports Jacob Hanna Read More »
This is a guest post on ISSCR 2013. By Dr. Susan Lim A record 4100 delegates attended the 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), held at the Convention and Exhibition Center in Boston from 12-15 June 2013. Co-sponsored by the Harvard Stem Cell Institute, the Meeting featured 7 Plenary
Delightful overview of ISSCR 2013 by guest blogger Dr. Susan Lim Read More »
Is Advanced Cell Technology (ACT) on the road to cure Multiple Sclerosis (MS) using stem cells and specifically MSCs? Some folks seem to think it’s quite possible, but I remain skeptical. Still there have been some interesting developments. ACT has a relatively new patent filing for a mesenchymal stromal cell (MSC) product that was just
ACT patent filing for MSCs: of Dancing Mice & Multiple Sclerosis Read More »